Correction
The original article cited the following retracted reference: “18. Yan, J.; Yang, S.; Tian, H.; Zhang, Y.; Zhao, H. Copanlisib promotes growth inhibition and apoptosis by modulating the AKT/FoxO3a/PUMA axis in colorectal cancer. Cell Death Dis. 2020, 11, 943.”
Replacements have been applied for the following:
- 18.
- Destefanis, R.A.; Schmitz, A.E.; Steimle, A.K.; Payne, S.N.; Sha, G.C.; Olson, A.M.; Cornelio, A.; Lippert, A.E.L.; Kraus, S.G.; Johnson, K.A.; et al. BCL-2 Family Inhibition Enhances mTORC1/2 Inhibition in PIK3CA-Mutant Colorectal Cancer. Mol. Cancer Ther. 2025, OF1–OF14. https://doi.org/10.1158/1535-7163.MCT-24-1096.
- 19.
- Udgata, S.; Stoecker, J.N.; Shen, X.; Pasch, C.A.; Deming, D.A. Co-existent PIK3CA and ARID1A mutations lead to enhanced sensitivity to PI3K inhibition through PUMA induction by FOXO3a and p53/p21. In Proceedings of the American Association for Cancer Research Annual Meeting 2025, Part 1 (Regular Abstracts), Chicago, IL, USA, 25–30 April 2025; AACR: Philadelphia, PA, USA, 2025; p. 371.
With this correction, the order of some references has been adjusted accordingly. The authors state that the scientific conclusions are unaffected. This correction was approved by the Academic Editor. The original publication [1] has also been updated.
Reference
- Schmitz, A.E.; Udgata, S.; Johnson, K.A.; Deming, D.A. The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies. Biomedicines 2025, 13, 1319. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).